Serum Sulfonylurea Receptor-1 Levels After Acute Supratentorial Intracerebral Hemorrhage: Implication for Prognosis. 2022

Cheng-Jun Zhuge, and Cheng-Peng Zhan, and Ke-Wei Wang, and Xin-Jiang Yan, and Guo-Feng Yu
The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.

Sulfonylurea receptor-1 (SUR1) is implicated in acute brain injury. This study was designed to determine relationship between serum SUR1 levels and severity, early neurologic deterioration (END) plus clinical outcome after intracerebral hemorrhage (ICH). Serum SUR1 levels of 131 ICH patients and 131 healthy controls were quantified in this prospective, observational study. END was defined as an increase of 4 or more points in the National Institutes of Health Stroke Scale (NIHSS) score or death within 24 hours after admission. Patients with a modified Rankin scale (mRS) score of 3-6 at 90 days following onset were considered to experience a poor outcome. Serum SUR1 levels were substantially higher in patients than in controls. Serum SUR1 levels of patients were highly correlated with NIHSS score, Glasgow Coma Scale score, hematoma volume and ICH score. Compared with patients with END or mRS score of 0-2, other remainders had significantly elevated serum SUR1 levels. Serum SUR1 levels independently predicted END and 90-day poor outcome. Under receiver operating characteristic curve, serum SUR1 levels significantly predicted END and a poor outcome at 90 days after hemorrhagic stroke and its predictive value was similar to those of NIHSS score, Glasgow coma scale score, hematoma volume and ICH score. Serum SUR1 levels are highly correlated with severity, END and poor outcome after hemorrhagic stroke, indicating that serum SUR1 may be useful for risk stratification and prognostic prediction of ICH.

UI MeSH Term Description Entries

Related Publications

Cheng-Jun Zhuge, and Cheng-Peng Zhan, and Ke-Wei Wang, and Xin-Jiang Yan, and Guo-Feng Yu
March 2016, Acta neurologica Scandinavica,
Cheng-Jun Zhuge, and Cheng-Peng Zhan, and Ke-Wei Wang, and Xin-Jiang Yan, and Guo-Feng Yu
December 2021, Clinica chimica acta; international journal of clinical chemistry,
Cheng-Jun Zhuge, and Cheng-Peng Zhan, and Ke-Wei Wang, and Xin-Jiang Yan, and Guo-Feng Yu
February 2023, Clinica chimica acta; international journal of clinical chemistry,
Cheng-Jun Zhuge, and Cheng-Peng Zhan, and Ke-Wei Wang, and Xin-Jiang Yan, and Guo-Feng Yu
January 2022, Frontiers in aging neuroscience,
Cheng-Jun Zhuge, and Cheng-Peng Zhan, and Ke-Wei Wang, and Xin-Jiang Yan, and Guo-Feng Yu
October 2002, Epilepsia,
Cheng-Jun Zhuge, and Cheng-Peng Zhan, and Ke-Wei Wang, and Xin-Jiang Yan, and Guo-Feng Yu
July 1990, Schweizerische medizinische Wochenschrift,
Cheng-Jun Zhuge, and Cheng-Peng Zhan, and Ke-Wei Wang, and Xin-Jiang Yan, and Guo-Feng Yu
November 2020, World neurosurgery,
Cheng-Jun Zhuge, and Cheng-Peng Zhan, and Ke-Wei Wang, and Xin-Jiang Yan, and Guo-Feng Yu
December 2012, Maedica,
Cheng-Jun Zhuge, and Cheng-Peng Zhan, and Ke-Wei Wang, and Xin-Jiang Yan, and Guo-Feng Yu
April 1986, Neurosurgery,
Cheng-Jun Zhuge, and Cheng-Peng Zhan, and Ke-Wei Wang, and Xin-Jiang Yan, and Guo-Feng Yu
June 2008, Journal of neurosurgery,
Copied contents to your clipboard!